PHR 250321 20.00C(PHR250321C20000) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

Clear

All

Quotes

News

Learn

Help

All

News

Announcements

No matches yet

Operations too frequent. Please try again later.

Please check network settings and try again Refresh Refresh

History record

PHR250321C20000

Watchlist

0.00
0.000.00%

15min DelayClose Mar 27 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Analysts Are Bullish on These Healthcare Stocks: Phreesia (PHR), Acrivon Therapeutics, Inc. (ACRV)
TipRanksMar 26 09:10 ET · Ratings
Phreesia Participates in a Conference Call With Jefferies
TipRanksMar 20 10:50 ET
Jefferies Maintains Phreesia(PHR.US) With Buy Rating, Raises Target Price to $32
Moomoo NewsMar 19 07:31 ET · Ratings
Express News | Phreesia Inc : Jefferies Raises Target Price to $32 From $28
ReutersMar 18 10:22 ET
KeyBanc Maintains Phreesia(PHR.US) With Buy Rating, Maintains Target Price $30
Moomoo NewsMar 15 07:32 ET · Ratings
A Quick Look at Today's Ratings for Phreesia(PHR.US), With a Forecast Between $29 to $36
Moomoo NewsMar 14 09:00 ET · Ratings

Comments

Stock_Drift

Sep 16, 2024 02:27

$Phreesia (PHR.US)$

Moomoo AI

Dec 19, 2023 15:57

Investor confidence, reflected in a high P/S ratio and increasing share prices despite fluctuations, suggests anticipated persistent growth in Phreesia. Caution advised over sole reliance on price-to-sales ratios for investment decisions.

Phreesia, Inc.'s (NYSE:PHR) P/S Is Still On The Mark Following 43% Share Price Bounce

Moomoo Breakfast US

Jun 3, 2022 20:29

Columns Today's pre-market stock movers: TSLA, CHGG, OKTA, TPTX and more

Gainers:
• $Okta (OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo (STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics (TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals (AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...

Analysts Notebook

Apr 14, 2022 19:26

Columns Top upgrades and downgrades on 4/14

Upgrades
• $CDW Corp (CDW.US)$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva (CTVA.US)$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc. (CXW.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines (DAL.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller (FUL.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries (HII.US)$ : Cowen U...

Moomoo Breakfast US

Mar 31, 2022 20:53

Columns Today's pre-market stock movers: CLVS, PATH, DARE and more

Gainers:
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...